ALLFTD

The ALLFTD Study:
ARTFL-LEFFTDS Longitudinal Frontotemporal Lobar Degeneration: a multisite research consortium

[ALLFTD @allftd]

Excited about this paper from ALLFTD's Biomarker Core! https://t.co/B24YkAUPJz?

[The Lancet Neurology @TheLancetNeuro]

Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration https://t.co/iu77M0cxME

[ALLFTD @allftd]

@Henrypaulson5 @umichalzheimers Happy to have you on board, U of M!

[Dr. Nina Silverberg @Nina_BSil]

Congratulations to Dr. Marie Bernard, currently NIA's Deputy Director, for her new role! Looking forward to working with her as she takes the helm as NIH's Chief Officer for Scientific Workforce Diversity! https://t.co/aH77voKGFi

[ALLFTD @allftd]

There's some great advice in this thread.

[ALLFTD @allftd]

Recently published by ALLFTD investigators: Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration: https://t.co/kP36IhP7eB.
Open access!

[ALLFTD @allftd]

On May 13 & 14, @AFTDHope will convene its 2021 Annual #AFTDEducationConference online. The conference is free to attend & will feature interactive presentations by leading #FTD researchers & experts. Check out the full schedule and register today: https://t.co/iL98A3IUJU

[ALLFTD @allftd]

Congratulations Nicole Rust of @VisualMemoryLab @Penn, recipient of a 2021 @theNASciences Troland Research Award for significant advancements in experimental psychology and neuroscience! #NASaward #Psychology https://t.co/zRANZ15zCp

[LaShyra Nolen, MD, MPP @LashNolen]

In our latest in @Nature, @DrNicteMejia and I explicitly name different forms of racism as key drivers behind the disparate neurological outcomes we’ve seen during the pandemic.

We speaking all facts in 2021, y’all.

Check it out below!

https://t.co/UZgifOQvd0

@NatRevNeurol

[ALLFTD @allftd]

ALLFTD is proud to have supported this paper...

[UCSF Fein Memory and Aging Center @UCSFmac]

Plasma tau and neurofilament light in frontotemporal lobar degeneration and Alzheimer's disease. Plasma NfL is superior to plasma t-tau for the diagnosis & prediction of clinical progression. https://t.co/yh75LRYqIg @grinberg_t @SalvoSpinaSF @relajoie @JulioCRojas10 @AlbaLanguage

[Kirsten Bibbins-Domingo @KBibbinsDomingo]

Over 35 years, women MDs in academic medical centers were less likely than men to be promoted to assoc or full professor or to be appointed to dept chair - no apparent narrowing in gap over time

Women Physicians and Promotion in Academic Medicine | NEJM https://t.co/e26vtc0Fpp

[FTD Registry @EndFTDregistry]

Dedicated researchers & study volunteers are leading the way to increase knowledge about FTD. The hope is that people with an FTD gene mutation may one day be able to delay or prevent the emergence of the disease. #EndFTD Learn about the genetics of FTD: https://t.co/0FTpqRPvFp

[FTDtalk @FTDtalk]

Looking forward to the #AAIC2020 #FTDPIA today - @mtmclarke will be talking about our work on synaptic PET imaging in FTD #endftd

[Bluefield Project @BluefieldProj]

3/ YKL-40, TNF-α, and IL-6 , on the other hand, had limited utility as biomarkers of disease progression in inherited #FTD, as reported by #Ljubenkov and team from @allftd, who measured plasma from 239 familial FTD mutation carriers.

[ALLFTD @allftd]

Dr. Rosen's research found that different FTLD mutations are associated with different rates of brain atrophy, but the clinical course of f-FTLD is similar between the different mutations. You can watch his #AAIC20 presentation on-demand (OD-Biomarkers).#endFTD

[ALLFTD @allftd]

"Time to shift away from whites as the gold standard."-@beyoung40. Dr.Barnes, thank you for your insightful and informative plenary talk at #AAIC20 today.

[Lisa L. Barnes, PhD (Barnes Young) @beyoung40]

Please register for #AAIC20 this year and tune into my first plenary! Super excited to share some of the great work going on in the AD disparities space 👏🏽👏🏽😁

[ALLFTD @allftd]

Exciting talk by #Alector, reporting Phase 2 data for AL001. Watch it on-demand if you haven't seen it yet! OD-Drug Development: AL001 resorts CSF PGRN levels & normalizes disease-associated biomarkers in individuals with FTD due to heterozygous mutations in the GRN gene. #endFTD

[UC San Francisco @UCSF]

.@UCSFmac + @MayoClinic scientists will lead #ALLFTD, a new @NIH-funded research consortium that aims to speed the development of treatments for frontotemporal lobar dementia, the most common form of dementia in people under age 60. #FTD #FTLD
https://t.co/OlpNvz6th7

[Katie Brandt @KatieBrandt6]

Thank you @BostonGlobe for today's story about Jary Larsen, former AFTD Board Chair, highlighting $63 million in NIH funding for ALLFTD which includes UCSF, the Mayo Clinic, the Mass General FTD Unit and others - 2020 will move us forward. #ENDFTD https://t.co/g1vqDU1IcD

[Bluefield Project @BluefieldProj]

Congratulations to #ALLFTD investigators at 19 North American clinical sites on receiving $63M in NIH funding. ALLFTD is critical to understanding #FTD and developing drugs to treat it.

https://t.co/PVY1lERD7f